Top Markets
#1 TENDIES TENDIES +36.52%
#2 Cash Cat Cash Cat +27.12%
#3 Asteroid Shiba Asteroid Shiba +16.52%
#4 MarsCoin MarsCoin +15.71%
#5 OSK OSK +15.36%
#6 龙虾 (Lobster) 龙虾 (Lobster) +10.48%
#7 Tornado Cash Tornado Cash +9.52%
#8 Threshold Network Threshold Network +9.46%
#9 Kite Kite +7.57%
#10 Ardor Ardor +6.84%
Coin of the day
TENDIES TENDIES
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Oryzon Genomics S.A. Oryzon Genomics S.A.

Oryzon Genomics S.A.

ORY
Classifica tra le azioni #16842
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Prezzo delle azioni
$3.31
Ultima sincronizzazione: 2026-09-01
Capitalizzazione di mercato
$271.03M
Variazione (1 giorno)
-0.36%
Variazione (1 anno)
8.04%
Paese
ES
Scambia Oryzon Genomics S.A. (ORY)

Categoria

Healthcare
Rapporto P/B per Oryzon Genomics S.A. (ORY)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Oryzon Genomics S.A., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Oryzon Genomics S.A. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.828 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.5116 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.2199 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9942 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH